Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
NCT00923806 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2026-01-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was terminated due to poor accrual.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-09Also stopped (terminated): Alaunos Therapeutics, Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) (NCT05194735)
- 2026-10-28Results posted on the registry: The Methodist Hospital Research Institute, Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections + Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections (NCT04055623)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Alemtuzumab + MMF (NCT01436305)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Anti-thymocyte Globulin (Rabbit) + belatacept (NCT01856257)
- 2026-09-01Also stopped (terminated): Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, TCR-T therapy (NCT05438667)
- 2026-07-30Also stopped (terminated): ImCheck Therapeutics, an Ipsen company, ICT01 + Proleukin Injectable Product (NCT05307874)
- 2026-07-14Also stopped (suspended): David Wald, Vactosertib + Fludarabine Phosphate (NCT05400122)
- 2026-06-08Also stopped (withdrawn): Celularity Incorporated, CYNK-001 systemic and Intra cavity administration (NCT05218408)
- 2026-05-22Also stopped (terminated): University Hospital, Bordeaux, Interleukine-2 (NCT02389231)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT03745326)
- 2026-05-19Also stopped (terminated): National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT03745326)
- 2026-05-15Also stopped (terminated): Iovance Biotherapeutics, Inc., Lifileucel + LN-145 (NCT03645928)
- 2026-05-01Results posted on the registry: Gwynn Long, M.D., ADCT-301 (NCT04639024)
- 2026-05-01Also stopped (terminated): Gwynn Long, M.D., ADCT-301 (NCT04639024)
- 2026-03-23Results posted on the registry: Novartis Pharmaceuticals, CFZ533 - Cohort 1/Cohort 2 + Mycophenolate Mofetil (MMF) (NCT03663335)
- 2026-03-16Also stopped (terminated): Radboud University Medical Center, UCB-NK cells + IL-2 (NCT04347616)
- 2026-03-09Results posted on the registry: National Cancer Institute (NCI), E7 TCR cells + Aldesleukin (NCT02858310)
- 2026-02-23Also stopped (withdrawn): Intima Bioscience, Inc., Fludarabine + Cyclophosphamide (NCT05566223)
- 2026-01-15Also stopped (withdrawn): Camillo Ricordi and Jay Skyler, Anti-Thymocyte Globulin (ATG) + Interleukin 2 (NCT02586831)
- 2026-01-13Results posted on the registry: Beth Israel Deaconess Medical Center, Interleukin-2 (NCT02739412)
- 2025-12-24Also stopped (withdrawn): City of Hope Medical Center, Aldesleukin + Cyclophosphamide (NCT06626256)
- 2025-12-19Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Cyclophosphamide (NCT01319565)
- 2025-12-16Results posted on the registry: Fady M Kaldas, M.D., F.A.C.S., Basiliximab 20 MG (NCT04104438)
- 2025-12-08Results posted on the registry: University of Washington, Aldesleukin + Pembrolizumab (NCT03260504)
- 2025-12-08Also stopped (terminated): University of Washington, Aldesleukin + Pembrolizumab (NCT03260504)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision